Dipraglurant

Chemical compound
  • None
Identifiers
  • 6-Fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine
CAS Number
  • 872363-17-2
PubChem CID
  • 44557636
ChemSpider
  • 25069676
UNII
  • CV8JZR21A1
CompTox Dashboard (EPA)
  • DTXSID90236230 Edit this at Wikidata
Chemical and physical dataFormulaC16H12FN3Molar mass265.291 g·mol−13D model (JSmol)
  • Interactive image
  • c1ccnc(c1)C#CCCc2cn3cc(ccc3n2)F
InChI
  • InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2
  • Key:LZXMUJCJAWVHPZ-UHFFFAOYSA-N

Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).[1][2][3] As of 2014, it is in phase II clinical trials for this indication.[1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.[4]

See also

References

  1. ^ a b Martinez A, Gil C (29 July 2013). Emerging Drugs and Targets for Parkinson's Disease. Royal Society of Chemistry. pp. 255–. ISBN 978-1-84973-617-6.
  2. ^ Macor JE (2012). Annual Reports in Medicinal Chemistry. Academic Press. pp. 83–. ISBN 978-0-12-396492-2.
  3. ^ Fox SH, Brotchie JM (8 October 2014). Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer. pp. 323–. ISBN 978-1-4471-6503-3.
  4. ^ "Dipraglurant-ER for dystonia". Addex Therapeutics. Archived from the original on 2014-12-28. Retrieved 2014-12-28.

External links

  • Dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia - Addex Therapeutics Archived 2014-12-28 at the Wayback Machine
  • Dipraglurant-ER for dystonia - Addex Therapeutics Archived 2014-12-28 at the Wayback Machine
  • v
  • t
  • e
Group I
mGluR1Tooltip Metabotropic glutamate receptor 1
mGluR5Tooltip Metabotropic glutamate receptor 5
Group II
mGluR2Tooltip Metabotropic glutamate receptor 2
mGluR3Tooltip Metabotropic glutamate receptor 3
Group III
mGluR4Tooltip Metabotropic glutamate receptor 4
  • Antagonists: CPPG
  • MAP4
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
mGluR6Tooltip Metabotropic glutamate receptor 6
  • Antagonists: CPPG
  • MAP4
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
mGluR7Tooltip Metabotropic glutamate receptor 7
  • Antagonists: CPPG
  • MAP4
  • MMPIP
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
  • XAP044; Negative allosteric modulators: ADX71743
mGluR8Tooltip Metabotropic glutamate receptor 8
  • Antagonists: CPPG
  • MAP4
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Glutamate metabolism/transport modulators


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e